UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Amedisys

Loading...
Loading...
In a report published Friday, Jefferies & Company reiterated its Hold rating on Amedisys
AMED
, but lowered its price target from $14.00 to $9.00. Jefferies noted, “While we continue to believe that home nursing -- being the lowest-cost pre- and post-acute care option -- will have a key place in the continuum of care longer-term, AMED faces numerous near-term headwinds that will pressure its earnings outlook and the stock's valuation. Until these challenges dissipate, we recommend that investors stay on the sidelines.” Amedisys closed on Thursday at $10.50.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...